Skip to content

Aurinia closer to Phase 3 for lupus med

May 2, 2017

Last week, on April 20, during the National Kidney Foundation 2017 Spring Clinical Meeting in Orland, Florida, Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) announced some more promising news. The company exhibited positive 48-week results from its Phase 2b about voclosporin, a cure for Lupus Nephritis (LN), and gets closer to phase 3. In reaction, H.C. Wainwright top analyst Ed Arce maintains a Buy rating with a price target of $12.00, which represents an upside close to 72% compared to where the shares last traded.

“The new additional 48-week data indicate that voclosporin achieves statistical significance in all three pre-specified endpoints; speed of remission as measured by time to CR and partial response, reduction in Systemic Lupus Erthematosus Disease Activity Index (SLEDAI) score; and reduction in urine protein creatinine ratio. In our view, the most critically important new finding is that voclosporin achieved statistically significant improvement in reduction of SLEDAI score versus baseline in both dose groups at 24 and 48 weeks,” asserts Arce, confident on the success of Phase 3.

Moreover, “The new safety data sheds light into the treatment emergent adverse events (TEAEs),” which strengthens the analyst’s optimism. Arce concludes “In our view, voclosporin’s robust efficacy combined with a clean safety profile that eliminates side effects associated with prolonged exposure to high dose steroids is a game-changer in the management of LN.”


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: